University Systems Among Those Choosing Forte Research To Centrally Manage Research
Forte Research Systems announced that six leading clinical research institutions selected the company?s enterprise research system last year.
Forte Research Systems announced that six leading clinical research institutions—from university systems, hospitals and cancer groups--selected the company’s enterprise research system, last year. Forte also offers a specialized clinical trial management systems (CTMS).
The following organizations chose OnCore Enterprise Research system to centrally manage clinical research operations, with half implementing the system across multidisciplinary research groups:
- University of Colorado Denver
- University of Hawaii Cancer Center
- Baylor College of Medicine
- Hoosier Oncology Group
- Fox Chase Cancer Center
- Northside Hospital
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
